GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Investing.com - TD Cowen has lowered its price target on Novo Nordisk (NYSE: NVO) to $70.00 from $105.00 while maintaining a Buy rating on the stock. The new target sits within the broader analyst ...

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that “Americans must therefore have access to the most-favored-nation price.” ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...